NeuroPace (NPCE) Total Non-Current Liabilities (2020 - 2021)
NeuroPace's (NPCE) quarterly Total Non-Current Liabilities came in at $60.1 million in Q4 2021, down 3.12% year-on-year from $62.0 million in Q4 2020, and up 1.29% quarter-over-quarter from $59.3 million in Q3 2021.
NeuroPace (NPCE) Total Non-Current Liabilities (2020 - 2021) Analysis & Trends
NeuroPace's Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $60.1 million for Q4 2021.
- On a quarterly basis, Total Non-Current Liabilities fell 3.12% year-over-year to $60.1 million in Q4 2021; TTM through Dec 2021 was $60.1 million, a 3.12% decrease from a year earlier, with the FY2021 full-year figure at $60.1 million, down 3.12% from the prior year.
- Total Non-Current Liabilities grew to $60.1 million in Q4 2021 per NPCE's latest filing, from $59.3 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $65.1 million in Q1 2021 and bottomed at $58.1 million in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 20.94 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 41.44 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 41.88 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 2.64 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 3.53 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 9.85 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 24.21 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 3.57 Bn |
| 10 | NeuroPace | 494.96 Mn | 440.98 Mn | 18.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 60.06 Mn |
| Sep 30, 2021 | 59.30 Mn |
| Jun 30, 2021 | 58.06 Mn |
| Mar 31, 2021 | 65.06 Mn |
| Dec 31, 2020 | 61.99 Mn |